Drug intelligence / Profile preview

KNP-503

Development stage: Preclinical
Lead developer: Kanaph Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

KNP-503 is an orally available small molecule inhibitor targeting SHP2 (Src homology region 2-containing protein tyrosine phosphatase 2), also known as protein tyrosine phosphatase non-receptor type 11. Developed by Kanaph Therapeutics, it is classified as an antineoplastic agent and is being investigated for the treatment of various cancers. The drug acts by antagonizing SHP2, a key signaling molecule involved in cell proliferation and survival pathways that are often dysregulated in cancer. As of the latest updates, KNP-503 remains in preclinical development for cancer indications[1][2].

Other names: KNP 503KNP503KNP-503

Targets

PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)

Beyond the preview

Go deeper on KNP-503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KNP-503.

Explore the full profile